Titre :

Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.

Auteur(s) :

Cornu, Marjorie [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Bruno, Benedicte [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Loridant, Severine [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center (LIRIC) - U995
Navarin, Pauline [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Francois, Nadine [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lanternier, Fanny [Auteur]
Centre d'infectiologie Necker-Pasteur [CHU Necker]
Amzallag-Bellenger, Elisa [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dubos, Francois [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Mazingue, Francoise [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Sendid, Boualem [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center (LIRIC) - U995

Titre de la revue :

BMC pharmacology & toxicology

Nom court de la revue :

BMC Pharmacol Toxicol

Numéro :

19

Pagination :

81

Date de publication :

2018-12-06

ISSN :

2050-6511

Mot(s)-clé(s) en anglais :

Isavuconazole
Mucormycosis
Paediatrics
Drug-monitoring
Lichtheimia

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

BACKGROUND: The use of isavuconazole is approved for the management of invasive aspergillosis and mucormycosis, only in adults, as no paediatric pharmacology studies have been reported to date. Very few paediatric cases ...
Lire la suite >BACKGROUND: The use of isavuconazole is approved for the management of invasive aspergillosis and mucormycosis, only in adults, as no paediatric pharmacology studies have been reported to date. Very few paediatric cases have been published concerning the use of isavuconazole. Amphotericin B is the only antifungal agent recommended in paediatric mucormycosis, but adverse effects and especially nephrotoxicity, even with the liposomal formulation, could be problematic. In this context, the use of other antifungal molecules active on Mucorales becomes needful. METHODS: We describe a case of mucormycosis with rapid onset dissemination in a 3-year-old girl recently diagnosed with acute lymphocytic leukaemia. She was successfully treated with isavuconazole alone and then in combination with liposomal amphotericin B. Isavuconazole therapy was guided by therapeutic drug monitoring. CONCLUSIONS: This case offers new perspectives on the potential use of isavuconazole in children with mucormycosis, as an alternative or adjunct to liposomal amphotericin B.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-10-22T14:20:52Z
2020-03-20T16:48:36Z